Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis  by Kumar, Naveen et al.
lable at ScienceDirect
Tuberculosis 94 (2014) 282e286Contents lists avaiTuberculosis
journal homepage: http: / / int l .e lsevierhealth.com/journals / tubeDRUG DISCOVERY AND RESISTANCEPharmacokinetics and dose response of anti-TB drugs in rat infection
model of tuberculosis
Naveen Kumar, K.G. Vishwas, Mahesh Kumar, Jitendar Reddy, Manish Parab,
C.L. Manikanth, B.S. Pavithra, R.K. Shandil*
Department of DMPK and Animal Sciences, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, Indiaa r t i c l e i n f o
Article history:
Received 10 October 2013
Received in revised form
24 December 2013
Accepted 10 February 2014
Keywords:
Tuberculosis
Rat infection model
Front-line TB drugs
Phamacokinetics
PK/PD* Corresponding author. AstraZeneca India Pvt. Ltd
galore 560024, India. Tel.: þ91 80 23621212; fax: þ9
E-mail addresses: Kumar.naveen@astrazeneca.com
gmail.com (K.G. Vishwas), Maheshkn2424@gmail.
reddy@astrazeneca.com (J. Reddy), manish.parab11@
mani@gmail.com (C.L. Manikanth), dr.pavithrabs@
radha.shandil@astrazeneca.com (R.K. Shandil).
http://dx.doi.org/10.1016/j.tube.2014.02.004
1472-9792/ 2014 The Authors. Published by Elseviers u m m a r y
Robust and physiologically relevant infection models are required to investigate pharmacokinetic
epharmacodynamic (PK/PD) correlations for anti-tuberculosis agents at preclinical discovery. We have
validated an inhalation-based rat infection model of tuberculosis harbouring mycobacteria in a repli-
cating state, that is suitable for investigating pharmacokinetics and drug action of anti-tubercular agents.
A reproducible and actively replicating lung infection was established in Wistar rats by inhalation of a
series of graded inocula ofMycobacterium tuberculosis. Following an initial instillation ofw105 log10 CFU/
lung, M. tuberculosis grew logarithmically for the ﬁrst 3 weeks, and then entered into a chronic phase
with no net increase in pulmonary bacterial loads. Dose response of front-line anti-TB drugs was
investigated following pharmacokinetic measurements in the plasma of infected rats. Rifampicin,
Isoniazid, and Ethambutol dosed per orally exhibited bactericidality and good dose response with
maximal effect of 5.66, 4.66, and 4.80 log10 CFU reductions in the lungs, respectively. In contrast, Pyr-
azinamide was merely bacteriostatic with 1.92 log10 CFU/lung reduction and did not reduce the bacterial
burden beyond the initial bacterial loads present at beginning of treatment in spite of high Pyrazinamide
blood levels. Rat infection model with actively replicating bacilli provides a physiologically distinct and
pharmacologically relevant model that can be exploited to distinguish investigational compounds in to
bacteriostatic or bactericidal scaffolds. We propose that this rat infection model though need more drug
substance, can be used in early discovery settings to investigate pharmacology of novel anti-tubercular
agents for the treatment of active pulmonary tuberculosis.
 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Improved therapies for the treatment of tuberculosis are ur-
gently required to combat the global problem that accounts for
w1.5 million deaths annually with rapidly emerging multiple
drug resistant (MDR) and extensively drug resistant (XDR)
strains [1]. In this context, animal models of infection have
greatly facilitated screening and preclinical characterization of
newer anti-tubercular compounds [2e4]. Following the ﬁrst ever
demonstration of tubercular infection in Guinea pigs by Robert., Bellary Road, Hebbal, Ban-
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pigs, marmosets, macaques etc. have been experimentally
infected [6e9] to validate biologically and pharmacologically
relevant experimental tuberculosis models. The choice of animal
models for in vivo testing is largely dictated by economics, route
of infection, and the question that is being addressed. Mice have
been a model of choice for pharmacology studies for the prac-
tical reasons of size and cost [3,8,10]. In contrast, larger animals
like rabbits, guinea pigs, and monkeys are considered best for
understanding disease biology, immunology and tubercular pa-
thology because they present a similar spectrum of in vivo
phenotypes and pathology to that encountered in the human
host [11e13]. In larger animals like Guinea pigs, rabbits, and
nonhuman primates mycobacterial infection invariably leads to
the formation of heterogeneous, granulomatous necrotic lesions,
a hallmark of TB infection in the lung, whereas murine granu-
loma are less-organized collection of macrophages and lym-
phocytes without central caseous necrosis and are not hypoxicicense.
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pathology [9,14], immunology [15,16], host pathogen in-
teractions and mycobacterial latency [16] with low level chronic
bacillary infections. Rats are also widely used in pharmacokinetic
studies in general. Rat pharmacology model, though need more
drug substance for testing but may provide a viable option to
progress compounds that suffer with problem of high metabolic
clearance in mice. We have previously validated a chronic rat
infection model harbouring non-replicating bacteria for inves-
tigation of antimycobacterial activity in preclinical settings [17].
Here, we report the pharmacological relevance of a “replicating”
rat tuberculosis infection model for investigating preclinical
pharmacology. This rat infection model may help identifying
compounds active on replicating bacilli that may be relevant to
the treatment of active human tuberculosis.
2. Materials and methods
2.1. Drugs and reagents
Isoniazid (INH), rifampicin (RIF), ethambutol (EMB) pyr-
azinamide (PZA), hydroxypropyl methyl cellulose (HPMC), and
carboxymethyl cellulose (CMC) were purchased from Sigma
Chemical Co. USA.
2.2. Ethics statement and animals
The Institutional Animal Ethics Committee (IAEC), registered
with the Committee for the Purpose of Control and Supervision of
experiments on animals (CPCSEA), Government of India, approved
all animal experiment protocols and usage. Male Wistar rats were
purchased from Bioneeds, (Bangalore, India). Rats (7e8 weeks old)
were randomly assigned into groups of three per cage, and were
allowed one weeks acclimatisation before experimentation. Feed
and water were given ad libitum. Infected rats were maintained in
individually ventilated cages (Allentown Technologies, USA) in bio-
safety level 3 facilities, and all procedures on infected rats were
performed under strict biocontainment.
2.3. Aerosol infection
Mycobacterium tuberculosis H37Rv ATCC 27294, a strain sen-
sitive to all the standard antimycobacterial agents was used in
animal infection experiments. Bacterial cultures for animal in-
fections were prepared as described previously [18]. Rats were
infected with M. tuberculosis via inhalation procedure to achieve
acute respiratory infection as described previously [17]. A series
of bacterial inocula with increasing bacterial strength were aer-
osolised for 30 min cycle to deliver bacilli in to lungs to ﬁnd the
optimum inoculum size that delivered w105 CFU/lung. Infected
animals were randomly distributed in to groups of three and
housed for variable periods of time to establish the course of
infection. The course of mycobacterial infection was monitored
by enumeration of colony forming units (CFU) from excised lungs
at 3, 7, 14, 28, 46 and 70 days postinfection as described previ-
ously [17].
2.4. In vivo doseeresponse studies
Drug treatment started three days postinfection. Front-line anti-
TB drugs INH, RIF and EMB were administered orally, to rats as
suspensions in 0.5% (w/v) HPMC and 0.1% Tween 80 while PZAwas
in 0.25% CMC. INH and RIF(3e30 mg/kg), EMB (30e300 mg/kg) and
PZA (75e300 mg/kg), were administered for four weeks on a 6/7
day dosing format. At the end of dosing period animals wereeuthanized with CO2, lungs were removed, and processed for CFU
estimation. Lung homogenates were serially diluted in 10-fold
steps and plated onto Middlebrook 7H11 agar supplemented with
10% albumin dextrose catalase (Difco Laboratories). Plates were
incubated at 37 C with 5% CO2 for 3 weeks to obtain isolated
colonies.
2.5. Statistical analysis
The colony counts obtained from plating were transformed to
Log10(xþ1), where x equals the total number of viable tubercle bacilli
present in a given sample. Prism software version 4 (GraphPad
Software, Inc., San Diego, California) was used for ploting PK and PD
effects and statistical analysis by ANOVA.
2.6. Pharmacokinetics of INH, RIF, PZA and EMB in infected rats
INH, RIF (3 and 30 mg/kg), PZA (75 and 300 mg/kg) or EMB (30
and 300 mg/kg) were given orally once daily to male Wistar rats.
INH, RIF and EMB were suspended in 0.5% HPMC and 0.1% Tween
80, whereas PZAwas suspended in 0.25% CMC and administered at
a dose volume of 10 mL/kg. Animals infected with M. tuberculosis
were dosed with the drug substance for eighteen days, and on the
nineteenth day, the pharmacokinetics were determined in infected
animals. Blood samples (50 mL) were collected from animals into
Lithium-Heparin microvette tubes (Sarsted, Germany) at pre-dose,
0.083, 0.25, 0.5, 1, 2, 4, 6 and 24 h following administration by
puncturing the saphenous vein using a sparse sampling protocol.
Plasma (25 mL) was separated by centrifugation of blood samples at
10,000 rpm for 5 min at 4 C. Plasma proteins were precipitated
with acetonitrile, and the resulting samples were subjected to LC-
MS/MS analysis.
A 1 mg/mL stock solution of each drug was prepared in
Dimethylsulfoxide (DMSO) and diluted three-fold with blank rat
plasma to prepare standards ranging from 8 to 20,000 ng/mL.
Samples were mixed on a plate shaker and centrifuged at
4000 rpm for 20 min at 15 C. An aliquot (25 mL) of the super-
natant was mixed with 225 mL of mobile phase containing an in-
ternal standard. A 10 mL aliquot of the extracted sample was
injected into reverse phase C-18 analytical column on an HPLC
system coupled to a triple quadrupole Mass spectrometer. A pos-
itive ion mode with turbo spray and an ion source temperature of
450 C were utilized for mass spectrometric detection. Quantita-
tion was performed using multiple reaction monitoring (MRM)
mode. Linear regression plots of compounds to internal standard
peak area ratios vs compound concentrations were ﬁtted with 1/x
or 1/x2 weighting.
2.7. PK analysis
Pharmacokinetic (PK) analysis of the plasma concentratione
time relationships were performed with WinNonlin Phoenix
Software (version 6.2; Pharsight, USA). A Non-compartmental
analysis program, model 200, was used to calculate PK parame-
ters. The maximum concentration of drug in plasma (Cmax), time
to Cmax (Tmax), elimination half-life (t1/2), and AUC from time zero
to inﬁnity (AUC0eN) were estimated. AUC was computed using
trapezoidal rule (linear up and log down) and AUC0eN value was
considered only when AUC extrapolated was not more than 20%.
The estimation of terminal slope in order to calculate half-life was
made only when there were at least three sample points in the
terminal phase. Cmax/MIC, AUC/MIC in infected rats was calculated
by dividing these parameters by MIC values obtained from in vitro
assays.
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Figure 2. Efﬁcacy and Dose-response of front-line TB drugs in replicating (high dose)
aerosol infection model in rats following once daily treatment for four-weeks.
Log10 CFU counts (left lung lobe) were plotted against the range of drug regimens.
Isoniazid and Rifampicin (3, 10 and 30 mg/kg), Pyrazinamide (75, 150 and 300 mg/kg)
and Ethambutol (30, 100, 300 mg/kg) were tested. Each bar represents the mean U  U
SD CFU counts from a group of three animals. * Represents statistically signiﬁcant
reductions (p < 0.05) in CFU from untreated controls. MED: Minimum effective dose.
The minimum dose that holds the bacterial infection at the level of onset of treatment
(stasis). MBD: Minimum bactericidal dose. The minimum dose that results in a
2log10 CFU reduction in bacterial load in the lungs from the onset of treatment (cidal).
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3.1. Course of M. tuberculosis infection
Inhalation of three different bacterial inocula resulted in instil-
lation of lung bacterial loads as follows: An inoculum of 107 CFU/ml
delivered <104 CFU/lung while both 108 CFU/mL and 109 CFU/mL
inocula delivered respectively 4.6  106 CFU/lung and
4.8  106 CFU/lung (Data not shown). In the subsequent experi-
ments, reproducible infections were achieved with 109 CFU/mL
inocula. Therefore, 109 CFU/mL inoculumwas considered optimum
for further experiments. In a time course study, mycobacterial load
in the lungs increased logarithmically for the ﬁrst four weeks and
attained 7.24 0.15 log10 CFU/lung. Thereafter, bacterial replication
slowed down and the net bacterial load remained constant till 12
weeks (7.26  0.33 log10 CFU/lung) postinfection (Figure 1).
3.2. Dose response
The dose response of four front-line TB drugs was determined in
the replicating rat infection model following daily doses for 4
weeks. Three drugs, INH, RIF and EMB, exhibited good pharmaco-
dynamic dose response in the replicating infection model, and
achieved bactericidality (>2 log10 CFU/lung reduction from the
bacterial load at the time of beginning of treatment). While PZA did
not achieve bactericidality, INH achieved bactericidality at 30 mg/
kg (2.44 log10 CFU/lung reduction), and RIF at 30 mg/kg
(3.45 log10 CFU/lung reduction), and EMB at 300 mg/kg
(2.6 log10 CFU/lung reduction) as depicted in Figure 2. In the acute
model, INH, RIF and EMB exhibited good dose responses, while PZA
was largely ineffective and did not exhibit even bacteriostasis
across the dose range tested (Figure 2).
3.3. Pharmacokinetics of INH, PZA, RIF and EMB upon multiple
dosing
Blood concentrations of all the four drugs were estimated in the
plasma obtained from M. tuberculosis infected rats. INH exhibited
linear pharmacokinetics with Cmax of 8.3 mg/mL and exposure (AUC)
of 14.4 h mg/mL at 30 mg/kg. PZA achieved high Cmax (112.6 and
218.6 mg/mL), and exposures, (164.5 and 753.8 h mg/mL at 75 and0 7 14 21 28 35 42 49 56 63 70
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Figure 1. Course of infection of M. tuberculosis H37Rv in the lungs of Wistar rats
following high dose aerosol infection (109 CFU mL1 inoculum), monitored over a
period of 10wks.300 mg/kg) respectively. INH and PZA showed dose proportional
increase in exposure. In contrast, RIF and EMB exposures weremore
than dose proportional. RIF exhibited Cmax of 0.15 and 8.7 mg/mL,
and AUC was 1.0 and 54.7 h mg/mL at 3 and 30 mg/kg respectively.
EMB Cmax was 1.5 and 30.1 mg/mL, whereas AUC was 5.7 and
137.3 h mg/mL at 30 and 100 mg/kg respectively. Pharmacokinetic
parameters and timeeconcentration proﬁles of INH, RIF, ETM and
PZA are summarized in Table 1.
Further integration of pharmacokinetics data with MIC was
done to derive Cmax/MIC and AUC/MIC at different doses in infected
rats vs the maximum bacterial killing (Table 2). Increase in dose of
INH, RIF and ETM lead to increased Cmax/MIC and AUC/MIC as well
as net bactericidal effect in terms of CFU reduction (Table 2).
However, in case of pyrazinamide, Cmax/MIC and AUC/MIC
increased with dose but net bactericidal effect did not increase
much.
4. Discussion
Tuberculosis is a complex disease, and no single animal model
mimics the complete spectrum of pathobiology seen in humans
[2,6,9]. Nevertheless, animal models of tuberculosis have played a
signiﬁcant role in understanding disease biology [7e9,11e13] and
PKPD of new anti-tubercular agents [3,4,11,13,17e19]. Mice have
been the species of choice for in vivo efﬁcacy testing of new anti-TB
compounds due to practical reasons of size, cost and precedent ofTable 1
Oral multiple dose pharmacokinetic parameters of Isoniazid, Rifampicin, Pyr-
azinamide and Ethambutol in male Wistar rats infected with M. tuberculosis.
PK parameter Isoniazid Rifampicin Pyrazinamide Ethambutol
Dose (mg/kg) 3 30 3 30 75 300 30 300
Cmax (mg/mL) 0.31 8.38 0.15 8.69 112.6 218.6 1.52 30.04
AUC0eN (h mg/mL) 1.23 14.37 0.99 54.71 164.55 753.85 5.76 137.34
t1/2 (h) 2.65 1.04 4.41 2.44 1.05 1.04 2.16 2.90
Table 2
Integration of multiple dose pharmacokinetic parameters of Isoniazid, Rifampicin,
Pyrazinamide and Ethambutol obtained in male Wistar rats with minimum inhib-
itory concentration (MIC). C/MIC: Cmax divided by MIC; AUC/MIC: total plasma
exposure divided by MIC; Delta CFU: net bacterial colony forming unit reduction in
the lungs of rats following drug treatment at respective doses.
Compound Isoniazid Rifampicin Pyrazinamide Ethambutol
Dose (mg/kg) 3 30 3 30 75 300 30 300
MIC (mg/mL) 0.05 0.05 0.1 0.1 64 64 1 1
C/MIC 6.2 167.6 1.5 86.9 1.8 3.4 1.5 30.0
AUC/MIC 24.6 287.3 9.8 547.0 2.5 11.8 5.7 137.3
Delta CFU 0.24 4.60 0.12 5.60 1.10 1.90 1.30 4.80
N. Kumar et al. / Tuberculosis 94 (2014) 282e286 285reproducible experimental infections and therapeutic outcomes
[3,4,10,18e22]. However, mice do not develop the characteristic
human like granuloma with central necrosis and cavitary disease
that is seen with TB infections in larger animals [2,8,9,11,21,23],
except the recently reported C3HeB/FeJ strain of mice [24].
Currently, rats are widely being used in preclinical discovery
settings for investigating pharmacokinetics [25], toxicokinetics
[26], tubercular pathology [9,14e17,27] and immunology of latent
tuberculosis [15,16]. A signiﬁcant number of early discovery com-
pounds cannot be progressed due to high metabolic clearance in
mice. In the similar lines, a recent study that identiﬁed oxyphen-
butazone an old anti-inﬂammatory drug with potent activity on
non-replicating mycobacteria, reported inability to explore and
progress this compound further due to high mouse metabolic
clearance in mice and cost and complexity of models in higher
animal species [27]. A validated rat infection model may provide an
alternate pharmacology model to progress such anti-TB com-
pounds that cannot be tested in mice. However, need for relatively
large quantity of compound at early discovery stages remains the
limitation. The pharmacologic relevance of rat infection model was
further strengthened recently by demonstration of zones of low
oxygen tension (hypoxia) in the lungs of M. tuberculosis infected
Wistar rats by immunohistochemical methods [28].
We have previously validated and reported a rat model of TB
infection, for investigating pharmacodynamics of anti-tubercular
compounds in chronically infected Wistar rats [17]. The model
investigated pharmacodynamic effect of drugs on chronic/non-
replicating bacillary infection however, we had no information on
the underlying pharmacokinetics or the utility in investigating
replicating bacterial infections in rats. Here we report validation of
a replicating rat infectionmodel with feasibility of pharmacokinetic
sampling in M. tuberculosis infected rats to better link the expo-
sureeeffect relationships (Table 2).
Replicating bacilli are hallmarks of active pulmonary tubercu-
losis associated with fulminating clinical outcomes and spread of
air born infection in humans. Hence, replicating bacilli represent
distinctive phenotype vs non-replicating persistent tubercle bacilli
in vivo [32]. Evaluation of bactericidal activity of candidate drugs on
various phenotypes in respective models (replicating and chronic)
is needed for rational positioning of the candidate(s) in combina-
tion regimens. Pharmacodynamic studies on chronic bacillary in-
fections with anti-TB drugs are well documented in mice
[4,19,20,30,31] but not in rats [17]. Most anti-TB drugs are not
equally bactericidal on the two forms in vivo [29] due to phenotypic
drug tolerance exerted by immune and drug pressures in the hu-
man host. In the replicating infection model described here, drug
treatment started 3 days postinfection where bacilli are presumed
to be replicating either extracellularly or intracellularly within
macrophages in the absence of a characteristic granulomatous
environment. Replicating state of bacilli was evident from the
increasing (2.2 log10 CFU/lung) bacterial loads in lungs of untreated
animals during the four week drug treatment period similar toobservations in the acute or high dose aerosol (HDA) mouse
infection models [20,22,30].
Cell wall inhibitors like INH and EMB, that are presumed towork
best on replicating bacteria by virtue of being cell wall inhibitors
achieved bactericidal activity of >2 log10 CFU/lung reduction (INH
30 mg/kge2.44 log10 CFU reduction/lung and EMB 300 mg/kge
2.6 log10 CFU/lung reduction) compared to much inferior activity
(1.3 log10 CFU/lung and 0.94 log10 CFU/lung reduction) observed in
the chronic rat infection model harbouring non-replicating bacilli
reported by us previously [17]. In contrast, PZA had no activity on
replicating bacilli in this model in spite of high plasma Cmax (218 mg/
ml) and AUC0eN exposures (753 h mg/mL) at 300 mg/kg dose vs
0.62 log10 CFU/lung reduction in chronic rat infection model [17].
RIF, obviously was efﬁcacious (RIF 30 mg/kge3.45 log10 CFU/lung
reduction vs and 1.5 log10 CFU/lung reduction in chronic rat model)
since it works on both replicating and NRP phenotypes due to
targeting essential and central DNA machinery.
Lack of bactericidality of PZA in spite of signiﬁcant systemic
exposures demonstrates that rat infection model with replicating
bacilli is highly suitable for identifying compounds that preferen-
tially hit targets in replicating bacteria. The replicating rat infection
model adds value in differentiating investigational compounds into
bacteriostatic and bactericidal scaffolds, because the bacterial
numbers in untreated animals grow beyond the numbers present
at initiation of therapy similar to high dose mouse infection models
[22,31,32]. Since active TB exerts massive impact on health and well
being due to acute and debilitating nature of tuberculosis, animal
models mimicking active disease with replicating bacilli will be e
very useful in understanding disease process vis-a-vis identifying
speciﬁc inhibitors that are bactericidal in nature. Rats being
moderately sized animals offer a pathophysiologically relevant
[9,14,17,28] and better alternative pharmacology model for testing
of novel anti-TB compounds.
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